Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 3.52% and Operating profit at -26.66% over the last 5 years
2
With a growth in Net Sales of 5.84%, the company declared Very Positive results in Mar 25
3
With ROE of 4.15%, it has a fair valuation with a 1.44 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,849 Million (Mid Cap)
35.00
NA
0.36%
0.45
5.15%
1.30
Revenue and Profits:
Net Sales:
720 Million
(Quarterly Results - Sep 2025)
Net Profit:
71 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.73%
0%
2.73%
6 Months
-0.51%
0%
-0.51%
1 Year
47.04%
0%
47.04%
2 Years
67.76%
0%
67.76%
3 Years
2.4%
0%
2.4%
4 Years
-46.54%
0%
-46.54%
5 Years
-42.74%
0%
-42.74%
Zhejiang Tianyu Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.52%
EBIT Growth (5y)
-26.66%
EBIT to Interest (avg)
25.90
Debt to EBITDA (avg)
3.71
Net Debt to Equity (avg)
0.48
Sales to Capital Employed (avg)
0.46
Tax Ratio
11.00%
Dividend Payout Ratio
30.77%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.24%
ROE (avg)
4.61%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
1.44
EV to EBIT
40.74
EV to EBITDA
13.49
EV to Capital Employed
1.29
EV to Sales
2.42
PEG Ratio
0.06
Dividend Yield
0.33%
ROCE (Latest)
3.17%
ROE (Latest)
4.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
719.50
808.10
-10.96%
Operating Profit (PBDIT) excl Other Income
83.30
153.80
-45.84%
Interest
10.90
11.30
-3.54%
Exceptional Items
-0.10
0.10
-200.00%
Consolidate Net Profit
71.40
63.30
12.80%
Operating Profit Margin (Excl OI)
115.70%
80.70%
3.50%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -10.96% vs 7.15% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 12.80% vs -26.57% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,621.90
2,511.50
4.40%
Operating Profit (PBDIT) excl Other Income
444.20
452.80
-1.90%
Interest
56.00
51.20
9.37%
Exceptional Items
12.00
-5.00
340.00%
Consolidate Net Profit
55.90
27.40
104.01%
Operating Profit Margin (Excl OI)
41.30%
58.10%
-1.68%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 4.40% vs -5.59% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 104.01% vs 123.04% in Dec 2023
About Zhejiang Tianyu Pharmaceutical Co., Ltd. 
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






